TP53 and serous adenocarcinoma: Compared with the TCGA 2013 cohort, the higher proportion of TP53wt subtype and lower proportion of TP53 mutant subtype in the present cohort were speculated to be due to the younger patients enrolled in this study and fewer patients with high pathological risk (G3 and serous carcinomas) [13].